1. 76P Safety profile of adjuvant pembrolizumab (pembro) in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC): Pooled analysis of phase III clinical trials. (December 2022) Authors: Luke, J.J.; Long, G.V.; Robert, C.; Carlino, M.S.; Choueiri, T.K.; Haas, N.B.; O'Brien, M.E.R.; Paz-Ares, L.; Peters, S.; Powles, T.B.; Leiby, M.A.; Lin, J.; Zhao, Y.; Krepler, C.; Perini, R.F.; Pietanza, M.C.; Samkari, A.; Gruber, T.; Ibrahim, N.; Eggermont, A.M.M. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗